32 results
8-K
PNT
POINT Biopharma Global Inc.
13 Jun 23
Departure of Directors or Certain Officers
4:45pm
on the Company’s Nominating and Corporate Governance Committee.
Dr. Martell is a pharmaceutical executive. She started her pharmaceutical career at Pfizer
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
Inspections 100 Part III 101 Item 10. Directors, Executive Officers and Corporate Governance 101 Item 11. Executive Compensation 101 Item 12. Security …
PART III Item 10. Directors, Executive Officers and Corporate Governance Incorporated herein by reference to our definitive proxy statement for our
424B3
PNT
POINT Biopharma Global Inc.
11 Jul 22
Prospectus supplement
4:32pm
with the SEC on March 25, 2022, entitled “Item 10. Directors, Executive Officers and Corporate Governance,” “Item 11. Executive Compensation” and “Item 13
POS AM
PNT
POINT Biopharma Global Inc.
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
with the SEC on March 25, 2022, entitled “Item 10. Directors, Executive Officers and Corporate Governance,” “Item 11. Executive Compensation” and “Item 13
DEF 14A
bimxneaqahjymdtza
28 Apr 22
Definitive proxy
8:36am
424B3
6l2y0z60x220pstmzjt
31 Mar 22
Prospectus supplement
11:42am
POS AM
cvmcboxm8nt5k juhp
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
qn1hs3y52u5eia6
5 Aug 21
Prospectus supplement
4:26pm
8-K
EX-3.2
npn756x dw
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
8-K
9jr2ku
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
424B3
ycjmmzkpuw3jm7kfbn
9 Jun 21
Prospectus supplement
4:42pm
S-4/A
15hrv4
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
r49 j0128yc7uqqb
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
8-K/A
EX-2.1
xfzg cijs
18 Mar 21
Financial Statements and Exhibits
9:08am
10-K
EX-4.2
ja8jg
5 Mar 21
Annual report
8:13am